Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30? What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Hosted on MSN12d
Here's Why You Should Add Vertex Stock to Your Portfolio NowVertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Investors need to pay close ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
This readout is viewed as a significant potential catalyst for Vertex's stock, as success in chronic pain could substantially expand the market opportunity for the company's pain franchise.
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback